[Efalizumab. Long-term Treatment of Psoriasis]

Overview

Journal Hautarzt

Specialty Dermatology

Date 2005 Aug 13

PMID 16096737

Citations 1

Authors

J C Prinz

Affiliations

Soon will be listed here.

Abstract

Efalizumab is a humanized monoclonal CD11a-antibody. It inhibits T-cell migration and activation which are essential steps in the immunopathogenesis of psoriasis. Clinical studies have demonstrated that efalizumab is efficient and safe in the treatment of chronic plaque psoriasis. Approximately 30% of patients achieve an improvement in PASI of > or =75% within 12 weeks, with further clinical benefit noted with continued therapy. Efalizumab thus appears as an important option in the long-term management of chronic plaque psoriasis.

Citing Articles

Noninvasive assessment of impaired endothelial function in psoriasis.

Ulusoy R, Karabudak O, Yokusoglu M, Kilicaslan F, Kirilmaz A, Cebeci B Rheumatol Int. 2009; 30(4):479-83.

PMID: 19529939 DOI: 10.1007/s00296-009-0995-3.

References

Jullien D, Prinz J, Langley R, Caro I, Dummer W, Joshi A . T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology. 2004; 208(4):297-306. DOI: 10.1159/000077660. View

Coffey G, Stefanich E, Palmieri S, Eckert R, Padilla-Eagar J, Fielder P . In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells. J Pharmacol Exp Ther. 2004; 310(3):896-904. DOI: 10.1124/jpet.104.067611. View

Bauer R, Dedrick R, White M, Murray M, Garovoy M . Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm. 2000; 27(4):397-420. DOI: 10.1023/a:1020917122093. View

Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I . Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005; 141(1):31-8. DOI: 10.1001/archderm.141.1.31. View

Menter A, Kosinski M, Bresnahan B, Papp K, Ware Jr J . Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol. 2004; 3(1):27-38. View

Long A, Mitchell S, Kashanin D, Williams V, Prina Mello A, Shvets I . A multidisciplinary approach to the study of T cell migration. Ann N Y Acad Sci. 2005; 1028:313-9. DOI: 10.1196/annals.1322.035. View

Vugmeyster Y, Kikuchi T, Lowes M, Chamian F, Kagen M, Gilleaudeau P . Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol. 2004; 113(1):38-46. DOI: 10.1016/j.clim.2004.06.001. View

Dedrick R, Walicke P, Garovoy M . Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol. 2002; 9(2-4):181-6. DOI: 10.1016/s0966-3274(02)00029-1. View

Werther W, Gonzalez T, OConnor S, McCabe S, Chan B, Hotaling T . Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996; 157(11):4986-95. View

10.

Gottlieb A, Krueger J, Bright R, Ling M, Lebwohl M, Kang S . Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol. 2000; 42(3):428-35. DOI: 10.1016/s0190-9622(00)90214-7. View

11.

Gottlieb A, Gordon K, Lebwohl M, Caro I, Walicke P, Li N . Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004; 3(6):614-24. View

12.

Prinz J . The role of T cells in psoriasis. J Eur Acad Dermatol Venereol. 2003; 17(3):257-70. DOI: 10.1046/j.1468-3083.2003.00720.x. View

13.

Leonardi C . Efalizumab in the treatment of psoriasis. Dermatol Ther. 2004; 17(5):393-400. DOI: 10.1111/j.1396-0296.2004.04042.x. View

14.

Menter A, Leonardi C, Sterry W, Bos J, Papp K . Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol. 2006; 54(4 Suppl 1):S182-8. DOI: 10.1016/j.jaad.2005.10.028. View

15.

Leonardi C, Papp K, Gordon K, Menter A, Feldman S, Caro I . Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005; 52(3 Pt 1):425-33. DOI: 10.1016/j.jaad.2004.09.029. View

16.

Papp K, Bissonnette R, Krueger J, Carey W, Gratton D, Gulliver W . The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol. 2001; 45(5):665-74. DOI: 10.1067/mjd.2001.117850. View

17.

Gottlieb A, Krueger J, Wittkowski K, Dedrick R, Walicke P, Garovoy M . Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002; 138(5):591-600. DOI: 10.1001/archderm.138.5.591. View